Mike Pompeo Speaks at CPA; Recalls Beginning of China Trade War
Mike Pompeo, former Secretary of State under President Trump, was the keynote speaker at CPA’s annual meeting on April 5, 2022. Here is what he told the gathering.
Is a Strong Dollar Really all That Important?
Ex-World Banker John Hansen explains why a strong dollar might not be as good as the Washington-Wall Street consensus would have us think.
At Latest ITC Hearing, Anti-Dumping and Trade Deals Holding Manufacturing Jobs Hostage
The International Trade Commission held its seventh roundtable discussion on the impacts of foreign trade on American workers and manufacturing. CPA Chairman Zach Mottl was one of the speakers.
Katherine Tai Hammered in Hearings on Free Trade, Market Access
It sounded like the 1980s in Congress this week. Free trade and open markets were all the rage in a Senate Finance Committee hearing and a House Ways and Means Committee hearing with America’s top trade diplomat, Katherine Tai.
Deglobalization: An Idea Whose Time Has Come
P&O Ferries is the largest operator of ferryboats between the British Isles and the European Continent, a $1.1 billion company carrying 10 million passengers a
Trade Commission Hears from Detroit Workers Left Behind by Trade
Black workers in Detroit have been “devastated” by globalization. A few Michigan steelworkers give the International Trade Commission an earful on offshoring in the latest series on how trade impacts local communities.
CPA Member Revere Copper to Massively Increase Copper Capacity
Revere Copper of Rome, NY to boost its copper production capacity by around 30 million tons. Their timing couldn’t be better.
The GATT at 75: Look on My Works, Ye Mighty, and Despair
Seventy-five years after the General Agreement on Tariffs and Trade that led to the WTO, how has it turned out for the U.S.?
These are China’s Two Lifelines to Russia So Far
Here’s all we know about how China is really helping Russia. And what will have to happen for Washington to impose sanctions.
House FDA Hearing: No Plan for Domestic Drug Manufacturing
A House committee hearing on the FDA focused on diversity in clinical trials, fast approval for cancer drugs, and no word on foreign vs domestic generic pharmaceutical labs.
